سعر يوريكودروب Uricodrop‏ 40مجم 20 قرص 2026

Uricodrop 40 mg (Marcyrl, Egypt), 20 film-coated tablets: febuxostat 40 mg, a xanthine oxidase inhibitor used to lower serum uric acid in gout.

• Adverse reactions in at least 1% of patients in controlled studies: liver function abnormalities, nausea, arthralgia and rash.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Contraindicated in patients being treated with azathioprine or mercaptopurine.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: gout patients with established cardiovascular disease had a higher rate of CV death with ULORIC than allopurinol (CARES); use only in patients with inadequate response to or intolerance of allopurinol, or for whom allopurinol is not advisable.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Gout flares frequently increase after initiation; NSAID or colchicine prophylaxis is recommended (up to 6 months) and febuxostat need not be stopped during a flare.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Fatal and non-fatal hepatic failure has been reported; obtain liver tests before starting and test promptly if symptoms of liver injury occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Azathioprine / mercaptopurineXanthine oxidase inhibition markedly increases 6-mercaptopurine exposure (clearance reduced about 83%); concomitant use contraindicated in the US label.DailyMed (U.S. National Library of Medicine)
• TheophyllineFebuxostat altered theophylline metabolism (about 400-fold increase in urinary 1-methylxanthine); use with caution.DailyMed (U.S. National Library of Medicine)
• Colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin, desipramineNo clinically significant interactions; may be used concomitantly.DailyMed (U.S. National Library of Medicine)

• Limited human data are insufficient to inform a drug-associated risk; no adverse developmental effects in rats and rabbits at exposures up to about 40 and 51 times the maximum recommended human dose.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on the breastfed infant; febuxostat is present in rat milk. Weigh benefits of breastfeeding against maternal need.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Febuxostat: 2-arylthiazole derivative that lowers serum uric acid by potent, selective, non-purine inhibition of xanthine oxidase (oxidised and reduced forms), which catalyses hypoxanthine to xanthine to uric acid (EU SmPC).